<p>Brain organoids have progressed from simple three-dimensional neuroepithelial aggregates to increasingly sophisticated systems that recapitulate key aspects of human neurodevelopment and disease. Despite rapid biological advances, their translational potential remains constrained by challenges in maturation, vascular integration, reproducibility, and scalable standardization. Recent innovations, including microfluidic perfusion platforms, synthetic extracellular matrices, vascularization strategies, and modular assembloid assembly, illustrate a shift from descriptive modeling to functionally integrated and experimentally controllable neural systems. However, increasing biological complexity introduces ethical and regulatory considerations that must be incorporated into translational research frameworks. These advances provide new opportunities to investigate human-specific developmental mechanisms and bridge the gap between in vitro modeling and in vivo neurobiology. Future progress will depend on balancing two complementary objectives: enhancing biological fidelity and improving experimental utility through increasingly controllable and design-driven organoid platforms with defined architecture, functionality, and reproducibility. In this context, brain organoids are emerging as bioengineered neural tissue systems that share important conceptual and technological foundations with next-generation artificial organ technologies. Continued advances in bioengineering, standardization, and systems-level integration are essential to maximize their translational impact on disease modeling, therapeutic testing, and regenerative neuroscience.</p>